Tags

Type your tag names separated by a space and hit enter

[Hyperhomocysteinemia and B-vitamin deficiency. Current clinical aspects].
Med Monatsschr Pharm. 2006 Aug; 29(8):291-302.MM

Abstract

Mild to moderate hyperhomocysteinemia has been recognized as an independent risk factor for coronary heart diseases, neurodegenerative diseases, osteoporosis, and pregnancy complications. Low intakes and decreased absorption of the B-vitamins are the most common causes of hyperhomocysteinemia, which is very prevalent in elderly people. The current review summarizes results from epidemiological studies and presents possible pathological mechanisms of hyperhomocysteinemia. In addition, the current study is a critical evaluation of results from several intervention studies that have been initiated for primary or secondary prevention of coronary and degenerative diseases. Lowering the risk of stroke is currently the most impressive effect of homocysteine-lowering-treatment and underlines the causal relationship. Available data is not sufficient for a final conclusion about the effectiveness of homocysteine-lowering in patients with coronary vascular diseases. Current recommendations stress the importance of measurement of plasma concentrations of homocysteine in patients with multiple risk factors. This allow early intervention with B-vitamins.

Authors+Show Affiliations

Klinische Chemie/Zentrallabor, Universitätsklinikum des Saarlandes, Homburg. kchwher@uniklinikum-saarland.deNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

16927597

Citation

Herrmann, Wolfgang, et al. "[Hyperhomocysteinemia and B-vitamin Deficiency. Current Clinical Aspects]." Medizinische Monatsschrift Fur Pharmazeuten, vol. 29, no. 8, 2006, pp. 291-302.
Herrmann W, Herrmann M, Obeid R. [Hyperhomocysteinemia and B-vitamin deficiency. Current clinical aspects]. Med Monatsschr Pharm. 2006;29(8):291-302.
Herrmann, W., Herrmann, M., & Obeid, R. (2006). [Hyperhomocysteinemia and B-vitamin deficiency. Current clinical aspects]. Medizinische Monatsschrift Fur Pharmazeuten, 29(8), 291-302.
Herrmann W, Herrmann M, Obeid R. [Hyperhomocysteinemia and B-vitamin Deficiency. Current Clinical Aspects]. Med Monatsschr Pharm. 2006;29(8):291-302. PubMed PMID: 16927597.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Hyperhomocysteinemia and B-vitamin deficiency. Current clinical aspects]. AU - Herrmann,Wolfgang, AU - Herrmann,Markus, AU - Obeid,Rima, PY - 2006/8/25/pubmed PY - 2006/9/26/medline PY - 2006/8/25/entrez SP - 291 EP - 302 JF - Medizinische Monatsschrift fur Pharmazeuten JO - Med Monatsschr Pharm VL - 29 IS - 8 N2 - Mild to moderate hyperhomocysteinemia has been recognized as an independent risk factor for coronary heart diseases, neurodegenerative diseases, osteoporosis, and pregnancy complications. Low intakes and decreased absorption of the B-vitamins are the most common causes of hyperhomocysteinemia, which is very prevalent in elderly people. The current review summarizes results from epidemiological studies and presents possible pathological mechanisms of hyperhomocysteinemia. In addition, the current study is a critical evaluation of results from several intervention studies that have been initiated for primary or secondary prevention of coronary and degenerative diseases. Lowering the risk of stroke is currently the most impressive effect of homocysteine-lowering-treatment and underlines the causal relationship. Available data is not sufficient for a final conclusion about the effectiveness of homocysteine-lowering in patients with coronary vascular diseases. Current recommendations stress the importance of measurement of plasma concentrations of homocysteine in patients with multiple risk factors. This allow early intervention with B-vitamins. SN - 0342-9601 UR - https://www.unboundmedicine.com/medline/citation/16927597/[Hyperhomocysteinemia_and_B_vitamin_deficiency__Current_clinical_aspects]_ DB - PRIME DP - Unbound Medicine ER -